Sugi Predict

Sugi Predict / Compounds / SCHEMBL1697148

SCHEMBL1697148

SCHEMBL1697148

CCCCCCC(=O)OC1CC[C@@]2(C)C(=CCC3C2CC[C@@]2(C)C3CC[C@@H]2[C@H](C)CCCC(C)C)C1

nearest known ligand 0.84

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ POLA1 P09884 1/20 0.70
▸ CYP46A1 Q9Y6A2 2/20 0.69
▸ USP2 O75604 2/20 0.65
▸ LMNA P02545 1/20 0.65
▸ ABCB1 P08183 1/20 0.65
▸ OSBP P22059 1/20 0.65
▸ RORC P51449 1/20 0.65
▸ OSBP2 Q969R2 1/20 0.65
▸ PLA2G2A P14555 1/20 0.62
▸ NPC1 O15118 1/20 0.59
▸ NR1H3 Q13133 2/20 0.58
▸ NPC1L1 Q9UHC9 1/20 0.58
▸ GBA1 P04062 2/20 0.58
▸ UGCG Q16739 2/20 0.58
▸ GBA2 Q9HCG7 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL161427 1.00 POLA1 (0.70) POLA1CYP46A1USP2LMNAABCB1
SCHEMBL4624683 1.00 POLA1 (0.70) POLA1CYP46A1USP2LMNAABCB1
SCHEMBL19919940 1.00 POLA1 (0.70) POLA1CYP46A1USP2LMNAABCB1
SCHEMBL17639910 1.00 POLA1 (0.70) POLA1CYP46A1USP2LMNAABCB1
SCHEMBL22620094 1.00 POLA1 (0.70) POLA1CYP46A1USP2LMNAABCB1
SCHEMBL21177689 1.00 POLA1 (0.70) POLA1CYP46A1USP2LMNAABCB1
SCHEMBL126915 1.00 POLA1 (0.70) POLA1CYP46A1USP2LMNAABCB1
SCHEMBL161428 1.00 POLA1 (0.70) POLA1CYP46A1USP2LMNAABCB1
SCHEMBL1667802 1.00 POLA1 (0.70) POLA1CYP46A1USP2LMNAABCB1
SCHEMBL18310374 1.00 POLA1 (0.70) POLA1CYP46A1USP2LMNAABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119959397-A Method for simultaneously detecting multiple cholesteric liquid crystal monomers in environmental medium 暨南大学 2025-05-09 — — CN claimed
CN-113429775-A UV (ultraviolet) photocuring liquid crystal structure color film and preparation method thereof 广东壮丽彩印股份有限公司 2021-09-24 — — CN claimed
CN-113248641-A Variable-temperature anti-counterfeiting material based on structural color and preparation method and application thereof 广东壮丽彩印股份有限公司 2021-08-13 — — CN claimed
CN-112708303-A Cholesteric liquid crystal structural color material, preparation method thereof and application thereof in image-text printing 广东壮丽彩印股份有限公司 2021-04-27 — — CN claimed
EP-3324932-B1 COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOPHILE FORMS NITTO DENKO CORP (JP) 2021-03-10 — — EP claimed
US-10300018-B2 Compositions and methods for nanoparticle lyophile forms NITTO DENKO CORPORATION (JP) 2019-05-28 — — US claimed
EP-3324932-A1 COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOPHILE FORMS Nitto Denko Corporation (JP) 2018-05-30 — — EP claimed
US-20170020819-A1 COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOPHILE FORMS NITTO DENKO CORPORATION (JP) 2017-01-26 — — US claimed
WO-2017015552-A1 COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOPHILE FORMS NITTO DENKO CORPORATION (JP) 2017-01-26 — — WO claimed
EP-2197495-A2 LIPOPEPTIDES FOR DELIVERY OF NUCLEIC ACIDS MDRNA, Inc. (US) 2010-06-23 — — EP claimed
WO-2009046220-A2 LIPOPEPTIDES FOR DELIVERY OF NUCLEIC ACIDS MDRNA, INC. (US) 2009-04-09 — — WO claimed
US-5846637-A Coated xerographic photographic paper XEROX CORPORATION (US) 1998-12-08 — — US claimed
US-5763128-A Simulated photographic-quality images on a substrate without curl XEROX CORPORATION (US) 1998-06-09 — — US claimed
JP-2223506-A — — None — — JP disclosed
US-12440445-B2 Fusogenic compounds for delivery of biologically active molecules NITTO DENKO CORPORATION (JP) 2025-10-14 — — US disclosed
US-20250250226-A1 IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF NITTO DENKO CORP (JP) 2025-08-07 — — US disclosed
US-5763128-A Simulated photographic-quality images on a substrate without curl XEROX CORPORATION (US) 1998-06-09 — — US disclosed
US-5653970-A CLEANING COMPOUNDS; COSMETICS LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) 1997-08-05 — — US disclosed
WO-1995002424-A1 LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN NORDION INTERNATIONAL INC. (CA) 1995-01-26 — — WO disclosed
JP-H02223506-A COSMETIC CONTAINING LIQUID CRYSTAL MIKIMOTO SEIYAKU KK 1990-09-05 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250250226-A1 IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF NCL, RNASE1, RNMT POLA1 346/4885CYP46A1 3886/4885USP2 4623/4885
US-20170020819-A1 COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOPHILE FORMS DDOST, RNASE1, DIS3 POLA1 1584/4885CYP46A1 675/4885USP2 2632/4885
US-10300018-B2 Compositions and methods for nanoparticle lyophile forms DDOST, RNASE1, DIS3 POLA1 1584/4885CYP46A1 675/4885USP2 2632/4885
US-12440445-B2 Fusogenic compounds for delivery of biologically active molecules FUS, NSF, FABP7 POLA1 4190/4885CYP46A1 1043/4885USP2 1993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.